ADA 2025 – Glycemic Goals & Hypoglycemia

Assessment of Glycemic Status

  • Core biomarkers & technologies

    • A1C, capillary blood-glucose monitoring (BGM) and continuous glucose monitoring (CGM) are the three pillars.
    • Key ADA 2025 recommendations
    • 6.1 Assess glycemia with A1C AND/OR CGM metrics (time-in-range/TIR, time-above-range/TAR, time-below-range/TBR).
    • 6.2 Test glycemia ≥ 2×/yr; every ≈ 3 mo if goals unmet, therapy changed, frequent dysglycemia, intercurrent illness, or rapid growth in youth.
    • Advantages of CGM vs. BGM
    • Fine-grained profile of glucose responses to meals, activity, insulin dosing.
    • Documented benefits in type 1, insulin-treated type 2, cystic-fibrosis–related diabetes: better control, less hypoglycemia, higher self-efficacy.

  • A1C testing specifics

    • Reflects ≈ 2–3 mo mean glycemia.
    • NGSP-certified assays exhibit high analytic accuracy; point-of-care devices enable in-visit intensification.
    • Interferences/limitations
    • Conditions altering red-cell turnover (hemolysis, ESA therapy, ESRD, pregnancy) or hemoglobin variants (HbSS, HbEE) may distort results.
    • Race/ethnicity should NOT be used to adjust A1C interpretation; genetic modifiers exist but are rare and ancestry-agnostic.
    • A1C ignores glycemic variability & hypoglycemia → combine with BGM/CGM data when variability is high.

  • Serum glycated protein assays

    • Fructosamine & glycated-albumin capture 2–4-wk glycemia; useful when A1C unreliable/unmeasurable (e.g.A homozygous Hgb variants).
    • Strongly correlated with chronic complications epidemiologically, but evidence base weaker than for A1C.

  • A1C ↔ average glucose conversion (ADAG study)

    • Correlation r=0.92r = 0.92; ADA reports eAG with every A1C.
    • Representative pairs (Table 6.1):
    • A1C=6%⇒eAG≈126  mg/dL\text{A1C}=6\% \Rightarrow \text{eAG}\approx126\;\text{mg/dL} (95 % CI 100–152).
    • A1C=7%⇒154  mg/dL\text{A1C}=7\% \Rightarrow 154\;\text{mg/dL}.
    • Caveats: data from 2008, older CGM tech, mixed capillary & CGM values; generalizability to modern uncalibrated CGM uncertain.

  • BGM guidance

    • Remains integral for insulin users; frequency/timing individualized per treatment, safety, cost.

  • CGM metrics & targets (Table 6.2)

    • Minimum "valid" dataset = ≥ 14 days with ≥ 70 % wear.
    • Key thresholds (non-pregnant adults)
    • TIR 70–180 mg/dL > 70 % (older adults > 50 %).
    • TBR < 70 mg/dL < 4 % (older adults < 1 %); TBR < 54 mg/dL < 1 %.
    • TAR > 180 mg/dL < 25 % (older adults < 50 %).
    • Coefficient of variation (CV) goal ≤ 36 % (≤ 33 % for sulfonylurea/insulin users if possible).
    • Ambulatory Glucose Profile (AGP) provides single-page, actionable visual (Fig 6.1). 70 % TIR ≈ A1C 7 %.
    • Older-adult CGM goals: ≥ 50 % TIR (~12 h/day), TBR < 1 % (< 15 min/day).

Glycemic Goals

  • Numeric goals for many non-pregnant adults (Table 6.3)

    • \text{A1C}<7\% (<53 mmol/mol53\,\text{mmol/mol}).
    • Pre-prandial capillary BG 80–130 mg/dL (4.4–7.2 mmol/L).
    • Peak 1–2 h post-prandial BG < 180 mg/dL (10 mmol/L).
    • CGM-based: TIR > 70 %; TBR targets as above.

  • Recommendation set 6.3–6.9

    • 6.3 Series: establish A1C < 7 % & TIR > 70 % where safe; stricter or looser if justified.
    • 6.4 Lower than 7 % acceptable if no hypoglycemia burden.
    • 6.5 Relax targets for limited life expectancy or treatment harms.
    • 6.6 De-intensify or switch off insulin/sulfonylurea/meglitinide if high hypoglycemia risk.
    • 6.7 Consider pill burden, tolerability, cost when benefits < harms.
    • 6.8 Reassess using individualized matrix (Fig 6.2) across health, function, preferences.
    • 6.9 Explicitly set goals during consultations → improved outcomes.

  • Individualization framework (Fig 6.2)

    • Axes: overall health, functional status, comorbidities, hypoglycemia risk, support systems.
    • Intensify for healthy patients with long life expectancy; de-intensify for complex/poor-health patients.

  • Microvascular evidence

    • DCCT (type 1): intensive therapy (mean A1C ≈ 7 %) cut retinopathy/nephropathy/neuropathy risk by 50–76 %; legacy effect sustained ≥ 20 yrs (EDIC).
    • UKPDS & Kumamoto (early type 2): intensive control (A1C ≈ 7 %) lowered microvascular events; durable benefit after 20 yrs.
    • Curvilinear risk curve: largest absolute benefit when reducing very high A1C to ~8 %; benefits still accrue 7 → 6 % but smaller.

  • Macrovascular/CVD outcomes

    • ACCORD, ADVANCE, VADT: near-normal A1C via insulin ↑ weight, hypoglycemia; no immediate CVD benefit, ACCORD ↑ mortality → caution in long-standing T2D.
    • Long-term follow-up (EDIC, UKPDS-20 yr, VADT-10 yr) shows reduced myocardial infarction & mortality → supports early durable control.
    • Modern agents (GLP-1 RA, SGLT2i) deliver CVD & renal benefit independently of A1C → initiate regardless of baseline A1C; two strategic options:
    1. Switch to GLP-1 RA/SGLT2i when already on multi-drug regimen lacking them.
    2. Add GLP-1 RA/SGLT2i for established CVD, CKD, or HF even if A1C at goal.

Adapting & De-intensifying Therapy

  • Metabolic memory: early intensive phase may confer decades-long benefit ⇒ later de-intensification acceptable if risk/benefit shifts.
  • Drivers to relax therapy: recurrent hypoglycemia, polypharmacy, high cost, limited life expectancy, cognitive decline.
  • Multiple RCTs demonstrate safe de-intensification with shared decision-making & close monitoring.

Hypoglycemia

  • Definitions (Table 6.4)

    • Level 1 (Hypoglycemia alert): 54\leq\text{BG}<70\;\text{mg/dL}.
    • Level 2 (Clinically significant): \text{BG}<54\;\text{mg/dL} → neuroglycopenia begins.
    • Level 3 (Severe): any BG with altered mental/physical status requiring assistance.

  • Key recommendations 6.10–6.19

    • Screen for past events each visit; formally assess impaired awareness & fear yearly.
    • Stratify risk (Table 6.5): insulin/sulfonylurea use ± major factors (recent events, CKD stage 5, cognitive impairment, etc.).
    • Use CGM for high-risk patients; set alerts at ≈70\approx70 mg/dL.
    • Treat conscious hypoglycemia with 15 g fast carbohydrate, recheck in 15 min; AID users often need only 5–10 g.
    • Prescribe glucagon to all insulin users or high-risk patients; teach family/caregivers; non-reconstituted nasal/injectable preferred.
    • One episode of level 2/3 should prompt therapy review & possible de-intensification.

  • Risk factors (Table 6.5)

    • Clinical: prior level 2/3 event, intensive insulin regimen, CKD, CVD, polypharmacy, female sex, age ≥ 75, high glycemic variability.
    • Social: food/housing insecurity, low income, low health literacy, alcohol/substance use, religious fasting.

  • Hypoglycemia awareness & assessment tools

    • Single-question screen (“Do you always feel low BG?”) → if "No", use detailed Clarke, Gold, Pedersen-Bjergaard, or HypoA-Q questionnaires.

  • Education & prevention (Table 6.7)

    • Structured DSMES covering symptoms, 15-15 rule, meter/CGM use, driving restrictions.
    • Regular review of carb counting, insulin timing, exercise adjustments.
    • Re-training programs (HARPdoc, BGAT) restore awareness & reduce events; even 2 wk without hypoglycemia can reset counter-regulation.

  • Glucagon products & costs (Table 6.6)

    • Injection powder 1 mg ≈ $206\$206 (AWP); nasal 3 mg ≈ $347\$347; pre-filled pens 0.5–1 mg $379\$379; dasiglucagon pen 0.6 mg $371\$371.
    • Check insurance formularies; replace at expiration; store per label.

  • Intercurrent illness & drug interactions

    • Sick-day rules: never omit basal insulin; ↑ monitoring; hydrate; test ketones if BG > 200 mg/dL200\,\text{mg/dL}.
    • Sulfonylureas + certain antibiotics (fluoroquinolones, TMP-SMX, azoles, clarithromycin, metronidazole) ↑ hypoglycemia → consider dose hold.

Hyperglycemic Crises (DKA & HHS)

  • Recommendations 6.20–6.21

    • Review past crises every visit; deliver structured education (ketone testing, sick-day protocol) to all type 1 and any patient with prior events.

  • Diagnostic criteria (Table 6.8)

    • DKA requires:
    1. Diabetes or BG ≥ 200 mg/dL200\,\text{mg/dL},
    2. Ketosis (β-OH-butyrate ≥ 3 mmol/L or urine ≥ "++"),
    3. Metabolic acidosis (pH < 7.3 and/or HCO₃ < 18 mmol/L).
    • HHS requires:
    1. BG ≥ 600 mg/dL600\,\text{mg/dL},
    2. Effective osmolality >300\,\text{mOsm/kg} [2×Na++glucose (mmol/L)]\bigl[2\times Na^+ + \text{glucose}\ (\text{mmol/L})\bigr] or total osmolality > 320,
    3. Minimal ketones (β-OH-B < 3 mmol/L),
    4. pH ≥ 7.3 & HCO₃ ≥ 15 mmol/L.
    • Euglycemic DKA: 10 % present with BG < 200 mg/dL200\,\text{mg/dL}; often precipitated by SGLT2i, pregnancy, prolonged fasting/alcohol.

  • Epidemiology & trends

    • Rates rising: type 1 ≈ 45–83 per 1,000 PY; type 2 ≈ 3 per 1,000 PY.
    • In-hospital mortality: DKA 0.2–1 %, HHS ≈ 0.8 %; mixed DKA-HHS > either alone.

  • Risk factors (Table 6.9)

    • Absolute insulin deficiency, youth, prior crisis, psychosocial issues, substance use, high A1C, SDOH barriers.
    • Drug-related: SGLT2i (type 1 >> type 2), steroids, atypical antipsychotics, immune checkpoint inhibitors.

  • Clinical presentation (Table 6.10)

    • DKA: hours-to-days; polyuria, polydipsia, weight loss, abdominal pain, Kussmaul respiration.
    • HHS: days-to-week; profound dehydration, mental-status change, often precipitating illness.
    • Hybrid DKA-HHS ≈ 1⁄3 of cases; treat as DKA but with larger fluid deficits.

  • Management pearls

    • Sick-day preparedness: maintain basal insulin, frequent BG & ketone checks, oral hydration, rapid-acting correction doses.
    • Mild DKA may be outpatient-managed if vitals stable & oral intake possible; otherwise hospital + IV insulin & fluids.
    • HHS generally warrants inpatient care due to severe dehydration & comorbid illness.

  • Prevention & post-crisis care

    • Intensive DSMES, problem-solving skills, peer/family support, CGM access reduce recurrence.
    • Screen & address SDOH (insulin affordability, equipment access); connect to community resources.

Practical Formulas & Conversions

  • eAG estimation: eAG (mg/dL)≈28.7×A1C(%)−46.7\text{eAG}_{\,(mg/dL)} \approx 28.7\times \text{A1C}(\%) - 46.7.
  • Effective osmolality (without urea): 2×[Na+ (mmol/L)]+glucose (mmol/L)2\times [Na^+\,(mmol/L)] + \text{glucose}\,(mmol/L).
  • Time-in-range ↔ A1C (approx.): every 5 % increase in TIR ≈ 0.4 % ↓ in A1C.

Ethical, Practical & Policy Considerations

  • Equity: racial differences in A1C likely genetic & minor → avoid race-based A1C interpretation; focus on equitable access to CGM & DSMES.
  • Cost: high prices of glucagon, CGM, and newer agents affect adherence; clinicians should check insurance formularies, use patient-assistance programs.
  • Shared decision-making: proven to improve adherence, satisfaction, and glycemic outcomes; documentation of individualized targets encouraged.
  • DCCT/EDIC, UKPDS, ACCORD, ADVANCE, VADT underpin micro- & macrovascular sections.
  • ADA Technology Section (Std Care §7) for detailed CGM/BGM guidance.
  • Older adults (Std Care §13) & pediatrics (§14) for age-specific targets.
  • Pregnancy management (§15), Hospital care (§16) for specialized scenarios.